ALNYLAM PHARMACEUTICALS, INC. Proceeds from Issuance of Private Placement
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Proceeds from Issuance of Private Placement of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2023-02-23
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for the quarter ending 2021-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for the quarter ending 2021-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for the quarter ending 2020-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for the quarter ending 2020-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for fiscal 2022 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for fiscal 2020 was $99.50M, a 75.13% decline from fiscal 2019.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from issuance of private placement for fiscal 2019 was $400.00M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $0.00 10-Q · filed 2021-10-28 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-03 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $99.50M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $99.50M 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | $99.50M 10-Q · filed 2021-08-03 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $0.00 derived: sum of 2 quarters · filed 2022-02-10 | $400.00M 10-K · filed 2022-02-10 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $400.00M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $400.00M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $21.38M 10-K · filed 2019-02-14 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $21.38M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $21.38M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 derived: sum of 3 quarters · filed 2019-02-14 | $14.30M 10-K · filed 2019-02-14 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $14.30M 10-Q · filed 2017-11-07 | $14.30M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $14.30M 10-Q · filed 2017-08-09 | $14.30M derived: sum of 3 quarters · filed 2018-02-15 | $14.30M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $14.30M 10-Q · filed 2017-05-05 | $14.30M derived: sum of 2 quarters · filed 2018-02-15 | $14.30M derived: sum of 3 quarters · filed 2018-02-15 | $14.30M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $0.00 derived: sum of 2 quarters · filed 2018-02-15 | $0.00 derived: sum of 3 quarters · filed 2018-02-15 | $89.02M 10-K · filed 2018-02-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $89.02M 10-Q · filed 2016-11-03 | $89.02M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $89.02M 10-Q · filed 2016-08-04 | $89.02M derived: sum of 3 quarters · filed 2017-02-15 | $89.02M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $89.02M 10-Q · filed 2016-05-04 | $89.02M derived: sum of 2 quarters · filed 2017-02-15 | $89.02M derived: sum of 3 quarters · filed 2017-02-15 | $89.02M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $0.00 derived: sum of 2 quarters · filed 2017-02-15 | $0.00 derived: sum of 3 quarters · filed 2017-02-15 | $723.04M 10-K · filed 2017-02-15 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $723.04M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $723.04M 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $723.04M 10-Q · filed 2015-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |